National network

The MEB performs its tasks in close cooperation with its national partners Health Care Inspectorate (GZ), National Institute for Public Health and the Environment (RIVM), Central Committee for Research Involving Human Subjects (CCMO), and Netherlands Pharmacovigilance Centre Lareb (Lareb).


In the area of pharmacovigilance, cooperation agreements have been concluded with the Pharmacoepidemiology Departments of Utrecht University (UU) and Erasmus University Rotterdam (Erasmus MC). Supported by this cooperation, the MEB plays a prominent role in Europe in the assessment of so-called Risk Management Plans. On the instructions of the MEB, the Netherlands Pharmacovigilance Centre Lareb manages the national spontaneous reporting system. Lareb collects and analyses reports of suspected adverse events reported by healthcare providers, patients, and marketing authorisation holders. If necessary, Lareb signals the MEB, so that the MEB can take further action.


In the area of oncology, the MEB has cooperated with the Netherlands Cancer Institute (NKI) in Amsterdam for a considerable time. For diabetes, cooperation agreements have been concluded with the diabetes centres of VU Medical Center in Amsterdam and Radboud UMC in Nijmegen.

Psychiatry, neurology, and vaccines

Cooperation with Utrecht University in the area of psychiatry and neurology and in the area of vaccines is being developed. In order to strengthen the evaluation of paediatric medicines, the MEB has established a focus group for paediatric medicines. This cooperation encourages a fruitful exchange of information and knowledge among the organisations. This results in an even better assessment of the benefit-risk balance of medicinal products.

Scientific basis

Many of the MEB's clinical assessors also work as specialists in academic hospitals, ensuring that their knowledge and own networks are and continue to be up-to-date.

Regular consultations

The MEB has regular consultations with various stakeholders, such as patient and consumer organisations, professional groups, and the umbrella organisations for the pharmaceutical industry. During these meetings, the participants discuss subjects of mutual interests and, where possible, make agreements to solve shared problems.